Fig. 1 · Structure

Documents & Downloads

Pravadoline (WIN 48098)

Cat. No. A10749 CAS 92623-83-1

COX inhibitor

Pravadoline (WIN 48,098) is antiinflammatory and prostaglandin synthesis inhibitor, acting through inhibition of the enzyme cyclooxygenase (COX).

In Stock

Publications for Pravadoline

1 publication citing this product

  1. Sharma P, .et al. , Org Lett, 2016, Feb 5;18(3):412-5 PMID: 26745849

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Pravadoline inhibited prostaglandin synthesis in mouse brain microsomes (IC50 5 μM; 95% confidence limits 1.7–13.3 μM). This assay does not establish COX isoform selectivity. [1]

In rat cerebellar membranes, pravadoline displaced an AAI radioligand with an IC50 of 3155 ± 54 nM (SE; n = 3). This binding result alone does not establish functional agonism or subtype selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

Prostaglandin synthesis in mouse brain microsomes

Biochemical assay · Mouse brain microsomes [1]

Pravadoline inhibited PG synthesis; indomethacin was the reference inhibitor. This endpoint does not establish COX isoform selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PG synthesis inhibitionIC50 5 μM (95% confidence limits 1.7–13.3 μM)[1]
PG synthesis inhibition by indomethacin (reference comparator)IC50 0.5 μM (95% confidence limits 0.4–0.7 μM)[1]

Literature-Reported Treatment Conditions

Method
In vitro microsomal assay
Reported limits
Concentration series, incubation time, vehicle and replicate count for the IC50 are unavailable in the retrieved report; detailed procedure is cited to reference 5, whose full text was not retrieved.
Methods and source locations

Compound reported in the paper: Pravadoline; Compound label in the paper: 1

Compound-level assay evidence; no salt equivalence or product-lot validation.

p. 128, Table I, compound 1 and indomethacin rows; footnote b; p. 129, Biological Evaluation

PG synthesis inhibition: Microsomal PG synthesis assay — p. 128, Table I, compound 1 and indomethacin rows; footnote b; p. 129, Biological Evaluation

PG synthesis inhibition by indomethacin (reference comparator): Same published assay table — p. 128, Table I, compound 1 and indomethacin rows; footnote b; p. 129, Biological Evaluation

AAI radioligand competition in cerebellar membranes

Biochemical assay · Male Sprague–Dawley rat cerebellar membranes [1]

Pravadoline displaced the AAI radioligand. Competition binding alone does not establish agonist efficacy or receptor subtype selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of 0.5 nM [3H]-(R)-(+)-21IC50 3155 ± 54 nM (SE; n = 3)[1]

Literature-Reported Treatment Conditions

Exposure duration
90 min
Method
30 °C; 0.5 nM radioligand; nonspecific binding defined with 1 μM unlabeled (R)-(+)-21.
Vehicle
Methanesulfonic acid/ethanol, ethanol or DMSO; vehicle effects controlled.
Reported limits
Pravadoline-specific solvent and competitor concentration series are not specified.
Methods and source locations

Compound reported in the paper: Pravadoline; Compound label in the paper: 1

Compound-level assay evidence; no salt equivalence or product-lot validation.

p. 128, Table I, compound 1, [3H]-AAI binding column and footnote d; p. 135, (Aminoalkyl)indole Binding Assay

Displacement of 0.5 nM [3H]-(R)-(+)-21: Radioligand competition; assays in triplicate — p. 128, Table I, compound 1, [3H]-AAI binding column and footnote d; p. 135, (Aminoalkyl)indole Binding Assay

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 92623-83-1
Applications COX inhibitor
Formula C23H26N2O3
Molecular Weight 378.5
Synonyms WIN 48098
SMILES
CC1=C(C2=CC=CC=C2N1CCN3CCOCC3)C(=O)C4=CC=C(C=C4)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Thomas E. D’Ambra, Kimberly G. Estep, Malcolm R. Bell, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. Journal of Medicinal Chemistry (1992). PMID: 1732519 DOI: 10.1021/jm00079a016 Source material

Publications

1 publication citing this product

  1. Sharma P, .et al. , Org Lett, 2016, Feb 5;18(3):412-5 PMID: 26745849

Added to your cart

View Cart Checkout
Loading...